# A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma

> **NCT05325801** · PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 9 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** BMCA and GPRC5D dual target CAR-T cells(OriC321)

## Key facts

- **NCT ID:** NCT05325801
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04
- **Primary completion:** 2024-03
- **Final completion:** 2025-03
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2022-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05325801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05325801, "A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05325801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*